
Midas Pharma Polska sp. z o.o.
Agents specialised in the sale of other particular products
Overview
Midas Pharma Polska is a company that provides a wide range of products and services across the pharmaceutical value chain, including starting materials, chemicals, drug substances, and drug products. They also offer contract development, contract manufacturing, and supply chain management services. Additionally, Midas Pharma specializes in medical devices and platform technologies such as hot melt extrusion.
Financials
Revenue history (in m)
Financial insight
- Possible Estonian CIT: Equity includes Art. 28d line items, but all amounts are 0 – this may be an accounting template or the first year of the regime.
From the notes
| Current income tax (CIT due) | $237,720 |
Filing timeliness
1 of 6 financial statements was filed late (for 2021, 76 days late). All were audited by a statutory auditor.
- 202527/06/2026
- 202407/07/2025
- 202302/07/2024
- 202205/07/2023
- 202129/09/2022
- 202030/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
Industry
Offer
- Chemicals
- Pharmaceutical intermediates
- Active ingredients
- Ready-made medicines
- Medical devices
- Contract manufacturing services
Websites
The site is available in: English and German.
- midas-pharma.comMidas Pharma – Solutions Across the Pharma Value ChainApache
Job offers
The company lists 1 job opening on its own careers page: midas-pharma.com/en/career.
Authorized Representatives
Manner of representation
If the company has a multi-member management board, two members of the management board acting jointly, or one member of the management board jointly with a commercial proxy, are authorised to make declarations concerning the company's property rights and obligations and to sign on behalf of the company.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
K.h.s. Pharma Holding Gmbh | 999 | $13,492.71 | 99.9% |
Others | 1 | $13.51 | 0.1% |
Beneficial owners
| Person | Rights |
|---|---|
Bank accounts
Registered as a VAT taxpayer on 2005-09-01.
40 1880 0009 0000 0011 0150 2000
29 1880 0009 0000 0011 0150 2004
13 1880 0009 0000 0011 0150 2001
Debt
No entries in the National Debtors Register (KRZ).
MSiG notices
| Publication date | Event | |
|---|---|---|
| Jun 2, 2017 | Return of additional payments |
Public aid
No public aid cases recorded in the last 10 years.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Magnapharm Poland sp. z o.o. | $90,512,785.67 | magnapharm.pl | ||
| Vantage Trading sp. z o.o. | $24,835,003.93 | vantages.pl | ||
| New Approach sp. z o.o. | $22,884,976.86 | newapproach.pl | ||
| Medyk-Lek Panek sp. z o.o. sp. k. | $20,167,374.20 | medyklek.pl | ||
| Bionorica Polska sp. z o.o. | $19,802,926.77 | bionorica.pl | ||
| Woerwag Pharma Polska sp. z o.o. | $16,858,061.27 | woerwagpharma.pl | ||
| MIP Pharma Polska sp. z o.o. | $17,756,306.34 | mip-pharma.de | ||
| Allpharm sp. z o.o. sp. k. | $13,461,628.01 | allpharm.pl | ||
| POL-NIL sp. z o.o. | $9,170,055.52 | pol-nil.com.pl | ||
| Ibsa Poland sp. z o.o. | $8,664,746.04 | ibsapoland.pl |
Change history
| Date | Event | |
|---|---|---|
| 2014-06-30 | Address change (Postępu 6, 02-676, Warszawa → Hankiewicza 2, 02-103, Warszawa) | |
| 2011-11-17 | Switch to PKD 2007 (3 PKD 2004 codes → 6 PKD 2007 codes) | |
| 2009-01-20 | Address change (Hankiewicza 2, 02-103, Warszawa → Postępu 6, 02-676, Warszawa) | |
| 2005-12-20 | Address change (Wilcza 31/1a, 00-544, Warszawa → Hankiewicza 2, 02-103, Warszawa) | |
| 2005-08-03 | Entered in the register |
FAQ
Last updated: 2026-07-15